Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Breast cancer is a heterogeneous disease with multiple molecular subtypes, each requiring tailored therapeutic strategies. The recent introduction of targeted therapies, immunotherapies, and antibody-drug conjugates has expanded treatment options, yet their efficacy varies depending on tumor subtype. This non-interventional study aims to identify novel predictive biomarkers of response or resistance to these emerging therapies. The Senocohort study will prospectively collect clinical, biological, imaging, and organoid-derived data from breast cancer patients, with a focus on hormone receptor-negative tumors. The ultimate goal is to improve precision medicine strategies and patient stratification
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Histologically confirmed breast cancer
Managed at Saint-Louis Hospital
No opposition to participation in research
Disqualifiers
Expressed opposition to research
Legal incapacity or under legal protection
Patients under State Medical Aid (AME)
Trial population
Patients aged 18 or older with a histologically confirmed diagnosis of breast cancer, treated at the Saint-Louis Hospital senology and breast surgery departments. Emphasis will be placed on hormone receptor-negative subtypes.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Patients follow-up
Other interventionBlood sampling, residual tissue material collection and clinical data collection
Treatment groups
500 Participants
are divided into 1 treatment groupGroup A: Breast Cancer Patients at Saint-Louis Hospital1 intervention
Trial outcomes
Primary outcomes
1
Number of Predictive Multimodal Biomarkers identified
Discovery and validation of molecular, cellular, and imaging biomarkers associated with response or resistance to therapies, evaluated on progression-free survival.
Time frame
Up to 10 yearsSecondary outcomes
1
Overall Survival Analysis by Biomarker Subgroup
Evaluation of overall survival based on biomarker-defined subgroups.
Time frame
Up to 10 years2
Multimodal biomarker performance
Assessment of the added value of combining multiple types of biomarkers (e.g., genomic + imaging).
Time frame
Up to 10 years3
Drug Sensitivity in PDO Models
Ex vivo response of PDOs to approved or experimental therapies, correlated with clinical outcomes.
Time frame
Up to 10 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: